A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.

Also called NCT07612657

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
VIVUS LLC (from the registry)
Registry
  • NCT NCT07612657
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07612657. Randomized; triple masking; primary purpose treatment. Start 2026-05-29 (anticipated); primary completion 2028-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
Acronym
TRANSCEND
Condition
Pulmonary Arterial Hypertension
Condition
Pulmonary Arterial Hypertension (PAH)
Condition
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Condition
Pulmonary Arterial Hypertension PAH
Condition
Pulmonary Arterial Hypertension WHO Group I
Intervention (Drug)
VI-0106
Intervention (Drug)
Placebo
Lead sponsor
VIVUS LLC (class: industry)

Record details

Record id
cardio:ct-nct07612657
Content hash
a2a3f83f112c438c4d89789cd9e0678777f4824c95c03071909547f789264f55